Y 25510

Drug Profile

Y 25510

Latest Information Update: 26 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class
  • Mechanism of Action Interleukin 1 beta stimulants; Interleukin 6 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Leucopenia; Thrombocytopenia

Most Recent Events

  • 26 Jun 2002 No development reported - Phase-I for Leucopenia in Japan (unspecified route)
  • 26 Jun 2002 No development reported - Phase-I for Thrombocytopenia in Japan (unspecified route)
  • 30 Mar 1998 Phase-I clinical trials for Leucopenia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top